about
A sensitized RNA interference screen identifies a novel role for the PI3K p110γ isoform in medulloblastoma cell proliferation and chemoresistance.BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.IGF-IR: potential role in antitumor agents.The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.Tailoring Medulloblastoma Treatment Through Genomics: Making a Change, One Subgroup at a Time.Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.Protein kinase B modulates the sensitivity of human neuroblastoma cells to insulin-like growth factor receptor inhibition.LG-19IMMUNOHISTOCHEMISTRY IS HIGHLY SENSITIVE AND SPECIFIC FOR THE DETECTION OF BRAF V600E STATUS IN PEDIATRIC LOW-GRADE GLIOMA.Review of molecular classification and treatment implications of pediatric brain tumors.Multiplex Detection of Pediatric Low-Grade Glioma Signature Fusion Transcripts and Duplications Using the NanoString nCounter System.Advances in Genomics Explain Medulloblastoma Behavior at the Bedside.Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma.A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases.LGG-16. LOCATION AND HISTOLOGY DICTATE THE LIKELIHOOD OF MOLECULAR EVENTS IN PEDIATRIC LOW-GRADE GLIOMA.LGG-18. MOLECULAR ALTERATIONS PREDICT RESPONSE TO CHEMOTHERAPY AND OUTCOME OF PEDIATRIC LOW-GRADE GLIOMA.Cerebellar tumors.LGG-10. EPIGENETIC/GENETIC/MORPHOLOGIC ANALYSES REVEAL CLINICAL/PROGNOSTIC INSIGHT OF PEDIATRIC LOW GRADE GLIOMASTGF-β Determines the Pro-migratory Potential of bFGF Signaling in MedulloblastomaAlterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomasIntegrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade GliomasLocoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma
P50
Q33926416-EB424705-71ED-4430-A47C-7A77665002BCQ35168770-14253C3A-05D5-4420-994D-729F24B2963EQ36581436-6FA20B98-59D6-4C80-8381-D334A5B39AC7Q37454384-C983F8DB-093A-49EF-8F79-3668B3CBE36DQ38670250-C5A29378-6000-451D-A3A8-6FB34C0DDC4CQ39285805-1994E576-EEAC-485C-8B80-AE03AA53FA1DQ39922005-89B367F5-CFC1-462B-8601-0BFEB4A4C225Q40229206-B74E1103-BE8B-42C3-90E8-A59B1367A49FQ46352959-180CC030-5925-4E10-8017-581280967BC4Q47190722-26D8859A-58F8-46FF-BE42-C12C8DD8BCD4Q47869458-A181D03E-AB5D-4221-B0FF-E2BB01A476CDQ48116800-71C402AF-C60E-47AD-A4AC-9D8F59979542Q48630455-88A2EF42-E06F-4430-B9C9-928788C146ECQ50422142-D146433A-681C-468F-B516-FBA9A9912649Q54878453-8A151671-384A-4842-B5FA-28DAFBB03E29Q54900968-A3D8EB1C-6011-4C71-94F3-888F49BBC6EFQ55456857-4C5ACD7E-98E9-4EE4-BA79-37F0A94F3EB4Q57841501-6B0BAE40-254A-4CB1-9721-1A37CAECA5C8Q89291593-B431B998-1A32-4455-B9F1-F74773079ECAQ90288010-D3698E6D-16CB-4305-B4B3-48CB884DB030Q91914550-40B40CB8-44E3-4E31-977E-7624273C9E97Q93271206-F2A36087-9293-4E50-9843-C273C0183F77
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-3136-9241
@en
name
Ana Guerreiro Stucklin
@ast
Ana Guerreiro Stucklin
@en
Ana Guerreiro Stucklin
@es
Ana Guerreiro Stucklin
@nl
type
label
Ana Guerreiro Stucklin
@ast
Ana Guerreiro Stucklin
@en
Ana Guerreiro Stucklin
@es
Ana Guerreiro Stucklin
@nl
altLabel
Ana Guerreiro-Stucklin
@en
prefLabel
Ana Guerreiro Stucklin
@ast
Ana Guerreiro Stucklin
@en
Ana Guerreiro Stucklin
@es
Ana Guerreiro Stucklin
@nl
P106
P21
P31
P496
0000-0003-3136-9241